David Robinson is reporting for the Rockland/Westchester Journal News federal authorities appear to be ready to tighten restrictions on CBD-brand cannabis products just as New York's recreational marijuana push is getting a restart. CBD, or cannabidiol, is typically sold as cannabis-derived oils, creams and capsules. Those products are legal in New York and across the country because they lack marijuana’s psychoactive element. The industry is currently on target to make $16 billion in sales by 2025, and concerns about bogus CBD marketing and products threatening users have led to calls for U.S. Food and Drug Administration oversight. Federal regulators have approved only medical grade CBD for treating severe epilepsy, making other CBD products claiming to treat a variety of ills into something akin to nutritional supplements. More than 70 percent of CBD extracts sold online were mislabeled regarding potency, according to a Penn Medicine study in 2017. In addition to poor quality controls, confusion about the legality of selling CBD-infused food and drinks has some consumers and businesses needing further clarification from state and federal regulators. The Food and Drug Administration will hold a key public hearing on May 31 regarding its regulation of cannabis and cannabis-derived products, such as CBD. Read the full story at lodged [dot] com.